Article
Hematology
Linus Angenendt, Isabel Hilgefort, Jan-Henrik Mikesch, Bernhard Schlueter, Wolfgang E. Berdel, Georg Lenz, Matthias Stelljes, Christoph Schliemann
Summary: High posttransplant magnesium levels have been independently associated with a lower relapse rate, an increased risk of acute graft-versus-host disease, and higher non-relapse mortality in patients with acute myeloid leukemia.
ANNALS OF HEMATOLOGY
(2021)
Article
Hematology
Masatomo Kuno, Satoshi Yamasaki, Nobuharu Fujii, Yasushi Ishida, Takahiro Fukuda, Keisuke Kataoka, Naoyuki Uchida, Yuta Katayama, Maho Sato, Daishi Onai, Toshihiro Miyamoto, Shuichi Ota, Satoshi Yoshioka, Takahide Ara, Akira Hangaishi, Yoshiko Hashii, Makoto Onizuka, Tatsuo Ichinohe, Yoshiko Atsuta, Yoshihiro Inamoto
Summary: The study compared myeloid neoplasms (MNs) following allogeneic hematopoietic cell transplantation (HCT) versus autologous HCT using a Japanese HCT registry database. The cumulative incidence of MNs was lower after allogeneic HCT than after autologous HCT, and those following allogeneic HCT developed in younger patients and sooner after HCT. Further research is needed to understand the mechanisms of MN development following allogeneic HCT.
AMERICAN JOURNAL OF HEMATOLOGY
(2022)
Article
Hematology
Sanam Shahid, Nicholas Ceglia, Jean-Benoit Le Luduec, Andrew Mcpherson, Barbara Spitzer, Theodota Kontopoulos, Viktoria Bojilova, M. Kazim Panjwani, Mikhail Roshal, Sohrab P. Shah, Omar Abdel-Wahab, Benjamin Greenbaum, Katharine C. Hsu
Summary: This study investigated the effects of allo-HCT on AML cells using a novel single-cell proteogenomic approach. The results demonstrated immune-related transcriptional signatures in posttransplant relapses, revealing dysfunction in activated natural killer cells and CD8+ T-cell subsets, as well as an expansion of dysfunctional T cells.
Review
Oncology
Li Xuan, Qifa Liu
Summary: Relapse is still the main reason for treatment failure in AML patients undergoing allo-HSCT. Evidence suggests that maintenance therapy post-transplantation, particularly targeted drugs like hypomethylating agents, FLT3 inhibitors, and isocitrate dehydrogenase inhibitors, could benefit AML patients, especially those at high risk.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Article
Oncology
Corentin Orvain, Eduardo Rodriguez-Arboli, Megan Othus, Brenda M. Sandmaier, H. Joachim Deeg, Frederick R. Appelbaum, Roland B. Walter
Summary: This study retrospectively analyzed 739 patients with de novo AML, 125 with antecedent hematologic disorder (AHD)/AML, and 115 with therapy-related AML who received allografts while in first or second remission. The results showed that relative to patients with de novo AML, relapse rates were similar for patients with AHD and therapy-related AML after multivariable adjustment, as were relapse-free survival and overall survival. Non-relapse mortality was higher for AHD AML. These findings suggest that the clinical history by itself has limited prognostic value for AML patients undergoing allografting.
Article
Hematology
Kevin-James Wattebled, Elodie Drumez, Valerie Coiteux, Leonardo Magro, Micha Srour, Paul Chauvet, Bruno Quesnel, Alain Duhamel, Ibrahim Yakoub-Agha, David Beauvais
Summary: Single-agent AZA does not appear to be an optimal drug for preventing posttransplant relapse in patients with high-risk myeloid malignancies. This study highlights the need for prospective studies of alternative therapies or combination approaches in the post-transplant setting.
ANNALS OF HEMATOLOGY
(2022)
Review
Oncology
Desiree Kunadt, Friedrich Stoelzel
Summary: The number of patients receiving allogeneic hematopoietic stem cell transplantation (alloHCT) has been increasing due to advances in transplant technology, supportive care, transplant safety, and donor availability. Acute myeloid leukemia (AML) is the most common indication for alloHCT, but disease relapse remains a major challenge. Maintaining a strong graft-versus-leukemia (GvL) effect is crucial for patient prognosis and long-term survival.
CANCER MANAGEMENT AND RESEARCH
(2021)
Review
Oncology
Enrico Maffini, Margherita Ursi, Francesco Barbato, Michele Dicataldo, Marcello Roberto, Elena Campanini, Elisa Dan, Francesco De Felice, Serena De Matteis, Gianluca Storci, Massimiliano Bonafe, Mario Arpinati, Francesca Bonifazi
Summary: Disease relapse post hematopoietic cell transplantation remains a major challenge, with novel cellular and biological therapies showing promise in treating acute leukemia relapse. Understanding the pathobiology of leukemia relapse is crucial for developing new therapeutic strategies, including targeted therapies and novel drug combinations.
FRONTIERS IN ONCOLOGY
(2022)
Article
Immunology
Shuang Fan, Tian-Zhong Pan, Li-Ping Dou, Yan-Min Zhao, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Xiao-Jun Huang, Xiao-Dong Mo
Summary: The study aimed to assess the efficacy of preemptive interferon-alpha (IFN-alpha) treatment in patients with acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in a real-world setting. The results showed that preemptive IFN-alpha treatment can eliminate measurable residual disease (MRD) in AML patients and improve leukemia-free survival.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Hematology
Riccardo Masetti, Edoardo Muratore, Davide Gori, Arcangelo Prete, Franco Locatelli
Summary: The selection of allo-HSCT for pediatric patients with AML in CR1 is still debated. This meta-analysis found that allo-HSCT improved overall survival and disease-free survival compared to chemotherapy in high-risk pediatric AML patients in CR1, but with an increased relapse rate. Sensitivity analysis confirmed the benefit of allo-HSCT on overall survival. Further research should focus on individualizing allo-HSCT indications based on molecular stratification and MRD monitoring.
ANNALS OF HEMATOLOGY
(2022)
Article
Hematology
Masamitsu Yanada, Takaaki Konuma, Satoshi Yamasaki, Shohei Mizuno, Shigeki Hirabayashi, Satoshi Nishiwaki, Naoyuki Uchida, Noriko Doki, Masatsugu Tanaka, Yukiyasu Ozawa, Masashi Sawa, Tetsuya Eto, Toshiro Kawakita, Shuichi Ota, Takahiro Fukuda, Makoto Onizuka, Takafumi Kimura, Yoshiko Atsuta, Shinichi Kako, Shingo Yano
Summary: This study aimed to compare the effect of disease status at the time of allogeneic hematopoietic cell transplantation (HCT) on post-transplant outcomes between acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The study found significant differences in the effect of disease status on post-transplant outcomes between AML and ALL patients. Risk of relapse and overall mortality increased in a stepwise manner for both diseases when transplanted in CR3+ or non-CR, with stronger relevance in ALL patients. Further investigation with measurable residual disease data is suggested for future studies.
ANNALS OF HEMATOLOGY
(2021)
Article
Immunology
Sun Yao, Chen Jianlin, Qiao Zhuoqing, Li Yuhang, Hu Jiangwei, Hu Guoliang, Ning Hongmei, Zhang Bin, Hu Liangding
Summary: This case report describes a patient with treated secondary AML who received tislelizumab in combination with azacitidine. While the patient achieved complete remission, they also experienced serious immune-related adverse events and graft vs. host disease, ultimately leading to death. This highlights the safety concerns of combining anti-PD-1 antibodies with azacitidine after allo-HSCT, particularly the risk of GVHD.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Hematology
Qingya Wang, Zeyin Liang, Hanyun Ren, Yujun Dong, Yue Yin, Qingyun Wang, Wei Liu, Bingjie Wang, Na Han, Yangliu Li, Yuan Li
Summary: This retrospective study analyzed data from 323 AML patients who underwent allo-HSCT at Peking University First Hospital. The study found that the annual number of transplantations increased steadily and there was a rise in high-risk cytogenetic and MRD-positive patients since 2013. The engraftment time has decreased over the past 20 years and both overall survival and disease-free survival have significantly improved, while non-relapse mortality has decreased since 2013. Risk factors for NRM were identified as transplantation before 2013, patients in CR2 or non-CR, and recipients older than 50 years, while non-CR and positive MRD were risk factors for recurrence.
ANNALS OF HEMATOLOGY
(2023)
Article
Oncology
Han-Zhou Qi, Na Xu, Jun Xu, Min Dai, Hui Liu, Guo-Pan Yu, Zhi-Ping Fan, Fen Huang, Peng-Cheng Shi, Jing Sun, Qi-Fa Liu, Yu Zhang
Summary: MLL rearrangement is common in solid tumor therapy-related acute myeloid leukemia (t-AML). Patients with MLL t-AML had poorer prognosis compared to non-MLL t-AML and MLL de novo AML, but allogeneic hematopoietic stem cell transplantation (allo-HSCT) could potentially improve outcomes for MLL t-AML.
AMERICAN JOURNAL OF CANCER RESEARCH
(2021)
Review
Oncology
Masamitsu Yanada, Kaito Harada, Yoshimitsu Shimomura, Yasuyuki Arai, Takaaki Konuma
Summary: Conditioning regimens are crucial in preventing AML relapse after HCT. Reduced-intensity conditioning has made HCT safer, and registry data can evaluate the effectiveness of different regimens.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Juan Carlos Hernandez-Boluda, Arturo Pereira, Nicolaus Kroeger, Dietrich Beelen, Marie Robin, Martin Bornhaeuser, Emanuele Angelucci, Antonin Vitek, Igor Wolfgang Blau, Riitta Niittyvuopio, Juergen Finke, Jan J. Cornelissen, Jakob Passweg, Peter Dreger, Eefke Petersen, Lothar Kanz, Jaime Sanz, Tsila Zuckerman, Nienke Zinger, Simona Iacobelli, Patrick Hayden, Tomasz Czerw, Donal McLornan, Ibrahim Yakoub-Agha
Summary: This study aimed to evaluate survival determinants in myelofibrosis patients undergoing allo-HCT and describe factors predicting post-HCT complications. Factors associated with increased mortality included age, Karnofsky Performance Status, graft failure, aGVHD, and disease progression/relapse. Risk of aGVHD and relapse incidence varied with donor type and conditioning regimen, with GVHD having a complex impact on relapse and survival.
Article
Biophysics
Arnon Nagler, Frederic Baron, Myriam Labopin, Emmanuel Polge, Jordi Esteve, Ali Bazarbachi, Eolia Brissot, Gesine Bug, Fabio Ciceri, Sebastian Giebel, Maria H. Gilleece, Norbert-Claude Gorin, Francesco Lanza, Zinaida Peric, Annalisa Ruggeri, Jaime Sanz, Bipin N. Savani, Christoph Schmid, Roni Shouval, Alexandros Spyridonidis, Jurjen Versluis, Mohamad Mohty
Summary: The survey revealed that detectable measurable residual disease (MRD) is a key prognostic factor in patients with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Most centers assessed MRD using techniques such as PCR and flow cytometry, with assessments conducted every 2-3 months for up to 2 years post-transplant. This survey marks the first step towards including MRD status as a routine registry parameter for acute leukemia.
BONE MARROW TRANSPLANTATION
(2021)
Letter
Biophysics
Johannes Schetelig, Jennifer Hoek, Stephan Stilgenbauer, Jan Moritz Middeke, Niels Smedegaard Andersen, Christopher P. Fox, Stig Lenhoff, Liisa Volin, Avichai Shimoni, Wilfried Schroyens, Michel van Gelder, Donald Bunjes, Anja van Biezen, Henning Baldauf, Liesbeth C. de Wreede, Olivier Tournilhac, Nicolaus Kroeger, Ibrahim Yakoub-Agha, Peter Dreger
BONE MARROW TRANSPLANTATION
(2021)
Article
Pharmacology & Pharmacy
Stephan Schaller, Frederico S. Martins, Pavel Balazki, Sonja Bohm, Joachim Baumgart, Ralf A. Hilger, Dietrich W. Beelen, Claudia Hemmelmann, Arne Ring
Summary: The PBPK model for treosulfan was developed using in vitro to in vivo extrapolation, showing low potential for DDI on CYP3A4 and CYP2C19, but no DDI on P-gp. Medicinal products with a narrow therapeutic index that are substrates for CYP3A4, CYP2C19, or P-gp should not be given during treatment with treosulfan.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2022)
Article
Oncology
Jan-Niklas Eckardt, Jan Moritz Middeke, Sebastian Riechert, Tim Schmittmann, Anas Shekh Sulaiman, Michael Kramer, Katja Sockel, Frank Kroschinsky, Ulrich Schuler, Johannes Schetelig, Christoph Roellig, Christian Thiede, Karsten Wendt, Martin Bornhaeuser
Summary: In this study, a multi-step deep learning approach was applied to automatically segment cells from bone marrow images, distinguish between AML samples and healthy controls with high accuracy, and predict the mutation status of NPM1. Unreported morphologic cell features were identified using occlusion sensitivity maps, enabling the DL model to provide accurate class predictions.
Correction
Biophysics
Johannes Schetelig, Jennifer Hoek, Stephan Stilgenbauer, Jan Moritz Middeke, Niels Smedegaard Andersen, Christopher P. Fox, Stig Lenhoff, Liisa Volin, Avichai Shimoni, Wilfried Schroyens, Michel van Gelder, Donald Bunjes, Anja van Biezen, Henning Baldauf, Liesbeth C. de Wreede, Olivier Tournilhac, Nicolaus Kroger, Ibrahim Yakoub-Agha, Peter Dreger
BONE MARROW TRANSPLANTATION
(2022)
Article
Biophysics
Christoph Schmid, Myriam Labopin, Nicolaas Schaap, Hendrik Veelken, Arne Brecht, Michael Stadler, Juergen Finke, Frederic Baron, Matthew Collin, Gesine Bug, Per Ljungman, Didier Blaise, Johanna Tischer, Adrian Bloor, Aleksander Kulagin, Sebastian Giebel, Norbert-Claude Gorin, Jordi Esteve, Fabio Ciceri, Bipin Savani, Arnon Nagler, Mohamad Mohty
Summary: This study analyzed 318 acute leukemia patients who received DLI after alloSCT, showing that preemptive DLI was effective in reducing MRD and increasing chimerism, thus improving survival rates for patients.
BONE MARROW TRANSPLANTATION
(2022)
Article
Hematology
Dietrich W. Beelen, Matthias Stelljes, Peter Remenyi, Eva-Maria Wagner-Drouet, Peter Dreger, Wolfgang Bethge, Fabio Ciceri, Friedrich Stoelzel, Christian Junghanss, Helene Labussiere-Wallet, Kerstin Schaefer-Eckart, Goetz U. Grigoleit, Christof Scheid, Francesca Patriarca, Alessandro Rambaldi, Dietger Niederwieser, Inken Hilgendorf, Domenico Russo, Gerard Socie, Ernst Holler, Bertram Glass, Jochen Casper, Gerald Wulf, Nadezda Basara, Maria Bieniaszewska, Gernot Stuhler, Mareike Verbeek, Ursula La Rocca, Juergen Finke, Fabio Benedetti, Uwe Pichlmeier, Anja Klein, Joachim Baumgart, Miroslaw Markiewicz
Summary: In older or comorbid patients with acute myeloid leukemia or myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation, treosulfan-based conditioning regimen shows better event-free survival and overall survival compared to a widely applied reduced-intensity conditioning busulfan regimen.
AMERICAN JOURNAL OF HEMATOLOGY
(2022)
Article
Hematology
Lisa Eisenberg, Christian Brossette, Jochen Rauch, Andrea Grandjean, Hellmut Ottinger, Jurgen Rissland, Ulf Schwarz, Norbert Graf, Dietrich W. Beelen, Stephan Kiefer, Nico Pfeifer, Amin T. Turki
Summary: This study developed machine learning models to predict mortality and cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation. The models integrated baseline patient data and time-dependent laboratory measurements, providing accurate risk predictions in a 21-day time window.
AMERICAN JOURNAL OF HEMATOLOGY
(2022)
Article
Oncology
Peter-Martin Bruch, Sascha Dietrich, Herve Finel, Ariane Boumendil, Hildegard Greinix, Thomas Heinicke, Wolfgang Bethge, Dietrich Beelen, Christoph Schmid, Hans Martin, Luca Castagna, Christof Scheid, Kerstin Schaefer-Eckart, Joerg Bittenbring, Juergen Finke, Henrik Sengeloev, Mael Heiblig, Jan Cornelissen, Patrice Chevallier, Mohamad Mohty, Stephen Robinson, Silvia Montoto, Peter Dreger
Summary: This retrospective study analyzed the outcomes of 162 adult patients with BPDCN who underwent a first HCT. The study found that MAC (especially TBI-based) significantly improved the prognosis of alloHCT recipients, and autoHCT could be considered for patients who are not eligible for MAC.
Article
Biophysics
Gesine Bug, Myriam Labopin, Riitta Niittyvuopio, Matthias Stelljes, Hans Christian Reinhardt, Inken Hilgendorf, Nicolaus Kroeger, Ain Kaare, Wolfgang Bethge, Kerstin Schaefer-Eckart, Mareike Verbeek, Stephan Mielke, Kristina Carlson, Ali Bazarbachi, Alexandros Spyridonidis, Bipin N. Savani, Arnon Nagler, Mohamad Mohty
Summary: Retrospective analysis compared two different conditioning regimens for AML patients undergoing HSCT and found that using FluTBI resulted in lower relapse probability but higher non-relapse mortality. There were no significant differences in overall survival and GRFS between the two groups. Therefore, FluTBI may be more suitable for younger patients below the age of 55.
BONE MARROW TRANSPLANTATION
(2023)
Article
Oncology
Julia-Annabell Georgi, Sebastian Stasik, Jan-Niklas Eckardt, Sven Zukunft, Marita Hartwig, Christoph Roellig, Jan Moritz Middeke, Uta Oelschlaegel, Utz Krug, Tim Sauer, Sebastian Scholl, Andreas H. Hochhaus, Tim Bruemmendorf, Ralph Naumann, Bjoern Steffen, Hermann Einsele, Markus Schaich, Andreas Burchert, Andreas Neubauer, Kerstin Schaefer-Eckart, Christoph W. Schliemann, Stefan Krause, Mathias Haenel, Richard Noppeney, Ulrich D. Kaiser, Claudia Baldus, Martin Kaufmann, Carsten Mueller-Tidow, Uwe E. Platzbecker, Wolfgang Berdel, Hubert Serve, Gerhard Ehninger, Martin Bornhaeuser, Johannes Schetelig, Frank Kroschinsky, Christian Thiede
Summary: Tandem-duplication mutations of the UBTF gene are associated with pediatric AML patients and inferior outcomes. By screening adult AML and MDS patients, UBTF-TDs were found to be rare but more common in younger patients and associated with MDS-related morphology and lower hemoglobin and platelet levels. These mutations were also associated with specific co-mutations and were stable over the disease course, making them a novel class-defining lesion in both pediatric and younger adult AML patients.
BLOOD CANCER JOURNAL
(2023)
Article
Hematology
Dietrich W. Beelen, Renate Arnold, Matthias Stelljes, Nael Alakel, Arne Brecht, Gesine Bug, Donald Bunjes, Christoph Faul, Juergen Finke, Georg-Nikolaus Franke, Ernst Holler, Guido Kobbe, Nicolaus Kroeger, Wolf Roesler, Christof Scheid, Stefan Schoenland, Michael Stadler, Johanna Tischer, Eva Wagner-Drouet, Knut Wendelin, Monika Brueggemann, Lena Reiser, Dieter Hoelzer, Nicola Goekbuget
Summary: Allogeneic hematopoietic stem cell transplantation (HCT) is the standard treatment for adult high-risk acute lymphoblastic leukemia (ALL) and has contributed to improved outcomes. In this study, the analysis of a cohort of patients showed that age and minimal residual disease (MRD) were strong predictors of non-relapse mortality (NRM) and relapse, respectively. The use of adapted conditioning strategies can enhance the success of stem cell transplantation.
TRANSPLANTATION AND CELLULAR THERAPY
(2022)
Meeting Abstract
Biophysics
Arnon Nagler, Myriam Labopin, Depei Wu, Goda Choi, Mahmoud Aljurf, Fabio Ciceri, Tobias Gedde-Dahl, Ellen Meijer, Riitta Niittyvuopio, Ivan Moiseev, Jean Henri Bourhis, Jan. J. Cornelissen, Gerard Socie, Yener Koc, Jonathan Canaani, Bipin Savani, Gesine Bug, Alexandros Spyridonidis, Sebastian Giebel, Eolia Brissot, Ali Bazarbachi, Jordi Esteve, Mohamd Mohty
BONE MARROW TRANSPLANTATION
(2021)
Article
Hematology
Roni Shouval, Joshua A. Fein, Myriam Labopin, Christina Cho, Ali Bazarbachi, Frederic Baron, Gesine Bug, Fabio Ciceri, Selim Corbacioglu, Jacques-Emmanuel Galimard, Sebastian Glebel, Maria H. Gilleece, Sergio Giralt, Ann Jakubowski, Silvia Montoto, Richard J. O'Reilly, Esperanza B. Papadopoulos, Zinaida Peric, Annalisa Ruggeri, Jaime Sanz, Craig S. Sauter, Bipin N. Savani, Christoph Schmid, Alexandros Spyridonidis, Roni Tamari, Jurjen Versluis, Ibrahim Yakoub-Agha, Miguel Angel Perales, Mohamad Mohty, Arnon Nagler
Summary: The study developed a contemporary disease-risk stratification system that categorized patients into five risk groups based on histology and remission status. The system was able to predict overall survival after allogeneic hematopoietic stem-cell transplantation and may serve as a benchmark for future studies on heterogeneous cohorts.
LANCET HAEMATOLOGY
(2021)
